Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment
Fig 5
Divergence of viral populations from the imputed founder sequence through time.
Each panel shows pairwise distances (y-axis) of unique plasma and QVOA-derived sequences from the imputed founder (means ±SD indicated for each timepoint with black horizontal lines) for Participant 1 (A), 2 (B), and 3 (C) over time (x-axis). Treatment status or imputed sequence tropism is indicated by color, shown in key. The times ART was initiated or suspended are shown with thick and thin black vertical lines, respectively. ART was suspended for 76 days, 26–31 days (on 3 separate occasions), and 3 years in Participants 1–3, respectively. Statistically significant differences (*p<0.05) in divergence of the RV/QVOA-derived viruses relative to the first RV timepoint as determined by 2-sample Wilcoxon rank-sum test are indicated. Also indicated are significant differences between the ART-interruption and RV after re-suppression relative to the latest RV timepoint during ART-suppression #1.